Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy

Authors

Arutselvan Natarajan¹, Shyam M. Srinivas¹, Carmen Azevedo¹, Lacey Greene¹, Anne-Laure Bauchet², Erwan Jouannot², Anne-Sophie Lacoste-Bourgeacq², Isabelle Guizon², Patrick Cohen², Anne-Laure Naneix³, Ohad Ilovich¹, Jordan Cisneros¹, Krithika Rupanarayan¹, Frederick T. Chin¹, Andrei Iagaru¹, Frederick M. Dirbas¹, Amer Karam¹, Sanjiv S. Gambhir¹

Organizations

1. Department of Radiology, Bio-X program, Molecular Imaging Program at Stanford (MIPS), Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA
2. Sanofi Aventis Research and Development, Vitry-sur-Seine, France
3. Centre de pathologie de Bichat, Paris, France

Abstract

An antigen-binding fragment (BFab) derived from a tumor-associated mucin 1–sialoglycotope antigen (CA6) targeting antibody (huDS6) was engineered. We synthesized a companion diagnostic positron emission tomography (PET) tracer by radiolabeling BFab with [⁶⁴Cu] to measure CA6 expression on cancer tissues prior to anti-human CA6 (huDS6-DM4 antibody-drug conjugate) therapy for ovarian and breast cancer patients. After chemotherapy, the ovarian patient received PET scan with ¹⁸F-2-fluoro-2-deoxyglucose ([¹⁸F]FDG: 10 mCi), followed by [⁶⁴Cu]-DOTA-BFab ([⁶⁴Cu]BFab; 5.5 mCi) 1 week later for PET scanning of CA6 expression and subsequent surgery. The breast cancer patient was treated with chemotherapy before primary tumor resection and subsequent [¹⁸F]FDG-PET scan. 4 weeks later the patient received of [⁶⁴Cu]BFab (11.7 mCi) for CA6 PET scan. Whole body [¹⁸F]FDG-PET of the breast cancer patient indicated FDG-avid tumor metastases to the liver, bilateral hila and thoracic spine, but no uptake was observed for the ovarian patient. Each patient was also imaged by PET/CT with [⁶⁴Cu]BFab at 1 and 24 hours after tracer administration. The [⁶⁴Cu]BFab tracer was well tolerated by both patients without adverse effects, and no significant tracer uptake was observed in both patients. Immunohistochemistry (IHC) data indicated CA6 expressions were weak to intermediate and matched with the [⁶⁴Cu]BFab-PET signals.

CovalX Technology Used

MALDI-ToF
HM4

Outcomes

ImmunoPET tracer was developed by radiolabeling an engineered antibody fragment, BFab (~72 kDa), with PET radioisotope ([⁶⁴CU]) to measure the carbonic anhydrase 6 (CA6) expression on cancer tissues in ovarian and breast cancer patients prior to anti-human CA6 therapy. Before performing any patients study, the quality assurance (QA) of DOTA-BFab, [⁶⁴ CU] and [⁶⁴ CU]BFab_PET Tracer was performed. One of the steps in this QA process included using Matrix-Assisted Laser Desorption Ionization modified with CovalX high-mass detector to detect the conjugation of mean DOTA chelates (c) per BFab (a) (~72 kDa).

Source